CN102203124A - 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 - Google Patents

淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 Download PDF

Info

Publication number
CN102203124A
CN102203124A CN200980137576XA CN200980137576A CN102203124A CN 102203124 A CN102203124 A CN 102203124A CN 200980137576X A CN200980137576X A CN 200980137576XA CN 200980137576 A CN200980137576 A CN 200980137576A CN 102203124 A CN102203124 A CN 102203124A
Authority
CN
China
Prior art keywords
amino acid
acid residue
sequence
oligomer
beta peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980137576XA
Other languages
English (en)
Chinese (zh)
Inventor
S·巴霍恩
H·希伦
R·埃达尔吉
L·巴雷特
P·理查森
郁立平
E·奥勒尼查克
J·哈兰
T·霍尔斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Abbott Laboratories
Original Assignee
Abbott GmbH and Co KG
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG, Abbott Laboratories filed Critical Abbott GmbH and Co KG
Publication of CN102203124A publication Critical patent/CN102203124A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200980137576XA 2008-07-25 2009-07-24 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 Pending CN102203124A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8358908P 2008-07-25 2008-07-25
US61/083589 2008-07-25
PCT/US2009/051721 WO2010011947A2 (en) 2008-07-25 2009-07-24 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES

Publications (1)

Publication Number Publication Date
CN102203124A true CN102203124A (zh) 2011-09-28

Family

ID=41570887

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980137576XA Pending CN102203124A (zh) 2008-07-25 2009-07-24 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途

Country Status (7)

Country Link
US (1) US20110092445A1 (enExample)
EP (1) EP2303920A4 (enExample)
JP (1) JP2011529084A (enExample)
CN (1) CN102203124A (enExample)
CA (1) CA2730804A1 (enExample)
MX (1) MX2011000975A (enExample)
WO (1) WO2010011947A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074924A (zh) * 2014-07-07 2017-08-18 艾伯维德国有限责任两合公司 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途
CN109851660A (zh) * 2019-03-20 2019-06-07 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽及其疫苗
CN109912687A (zh) * 2019-03-20 2019-06-21 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽药物

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2262526B1 (en) 2008-04-14 2015-12-02 Alzinova AB Stable amyloid beta monomers and oligomers
AU2009266552B2 (en) * 2008-07-01 2014-01-23 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9216217B2 (en) * 2010-03-03 2015-12-22 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2011156003A2 (en) 2010-06-09 2011-12-15 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
ES2628596T3 (es) 2010-11-29 2017-08-03 Akershus Universitetssykehus Procedimientos y composiciones para monitorizar la actividad fagocítica
WO2012072611A1 (de) * 2010-11-29 2012-06-07 Philipps-Universität Marburg SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
CA2857539C (en) * 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
US20130164217A1 (en) * 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
DE102012021222B4 (de) * 2012-10-27 2015-02-05 Forschungszentrum Jülich GmbH Verfahren zur Herstellung einer nanoporösen Schicht auf einem Substrat
EP2746402A1 (en) * 2013-03-12 2014-06-25 Academisch Medisch Centrum Method of prognosis of Alzheimers disease and substrates for use therein
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
EP3200681B1 (en) * 2014-09-05 2025-06-04 Presympto, Inc. Methods for detecting amyloid beta oligomers
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
WO2018005980A1 (en) * 2016-07-01 2018-01-04 The Scripps Research Institute Compositions and diagnostic methods related to transthyretin amyloid diseases
AU2018269964B2 (en) 2017-05-15 2022-07-07 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN108148115A (zh) * 2018-01-30 2018-06-12 中国药科大学 一种环肽合成新方法及其在药物开发中的应用
WO2019246140A1 (en) * 2018-06-18 2019-12-26 Emory University Parallel enzyme digestion for protein biomarker detection
JP7357354B2 (ja) * 2020-02-04 2023-10-06 国立大学法人京都大学 アミロイドβ４２架橋アナログペプチド
US12037375B2 (en) * 2021-12-30 2024-07-16 Korea University Research And Business Foundation Protein variant and composition for treating neurodegenerative disease using the same
KR102767892B1 (ko) * 2021-12-30 2025-02-14 고려대학교 산학협력단 신규한 단백질 변이체 및 이를 이용한 신경퇴행성 질환 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US20020132758A1 (en) * 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
US20070213512A1 (en) * 2002-10-01 2007-09-13 Krafft Grant A Amyloid beta peptide analogs and assemblies thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
US20090035295A1 (en) * 2005-03-05 2009-02-05 Abbott Gmgh & Co. Kg Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies
US8263558B2 (en) * 2005-11-30 2012-09-11 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
SI2091948T1 (sl) * 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074924A (zh) * 2014-07-07 2017-08-18 艾伯维德国有限责任两合公司 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途
CN109851660A (zh) * 2019-03-20 2019-06-07 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽及其疫苗
CN109912687A (zh) * 2019-03-20 2019-06-21 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽药物

Also Published As

Publication number Publication date
US20110092445A1 (en) 2011-04-21
MX2011000975A (es) 2011-05-25
EP2303920A4 (en) 2011-11-09
EP2303920A2 (en) 2011-04-06
WO2010011947A3 (en) 2010-04-29
CA2730804A1 (en) 2010-01-28
WO2010011947A2 (en) 2010-01-28
JP2011529084A (ja) 2011-12-01

Similar Documents

Publication Publication Date Title
CN102203124A (zh) 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
CN101830974B (zh) 淀粉样β(1‑42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
JP2023036606A (ja) 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
EA030777B1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
JPH09501159A (ja) 合成多重縦列反復ムチンおよびムチン様ペプチド、並びにそれらの利用
KR20080106432A (ko) ＩｇＧ와 ＦｃＲｎ의 결합을 차단하는 펩티드
JP2009115815A (ja) プリオン特異的ペプチド試薬を使用するｅｌｉｓａアッセイ
US20250076288A1 (en) Stabilized peptides for biomarker detection
WO2010010469A2 (en) Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US20200347099A1 (en) Synthetic Beta-Amyloid Peptides Capable of Forming Stable Antigenic Oligomers
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
CN111138521B (zh) 源自于afp抗原的短肽
JP2008527382A5 (enExample)
WO2004009770A2 (en) Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
WO2004063214A2 (en) Antibodies that specifically recognize sumo-conjugated proteins
WO1999046574A2 (en) Antibodies for assessing protein post-translational modification status and methods of making and using the same
WO2013151627A1 (en) Methods of treating glucose metabolism disorders
HK1118336B (en) Elisa assays using prion-specific peptide reagents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110928